Could cause temporary or reversible harm; serious harm is unlikely.
OOS results reported for the Dissolution (by UV) test.
| Brand name | THEOPHYLLINE |
| Generic name | THEOPHYLLINE |
| Active ingredient(s) | THEOPHYLLINE ANHYDROUS |
| Distributed by / for | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430 |
| NDC | 68462-356-01 |
| Full product label | Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | Nationwide in the USA |
| Quantity | 8,520 100-count bottles |
| Recall initiated | 2025-05-15 |
| Report date | 2025-06-04 |
| Recall completed | — |
| Recall number | D-0452-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗